Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 May 5;9:834593. doi: 10.3389/fmolb.2022.834593

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Xie, Tian, Tang, Zou, Zheng, Wu, Zeng, Wu, Xie and Xie.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Landscape of tumor immune microenvironment and drug sensitivity in patients with TNBC according to the CNI value (***, **, *, and ns indicate p < 0.001, < 0.01, < 0.05, and no significance, respectively). (A) Expression levels of various immune checkpoint molecules between the high- and low-CNI groups. (B) Violin plots of the proportions of different immune cell infiltration in TNBC with high-CNI and low-CNI. (C) Correlation between 50% inhibiting concentration (IC50) values of various chemotherapeutic drugs and necroptosis-related lncRNAs (r refers to correlation coefficient). (D) IC50 levels of some chemotherapeutic drugs between the high- and low-CNI groups in TNBC patients.